New Leadership at NIH
The NIH has appointed Dr. John Gaitanis, a pediatric neurologist known for his controversial views on autism, to lead its child health institute. This appointment has garnered significant attention due to the ongoing debates surrounding autism research.
Menopause and Brain Health
A recent cohort study has indicated a correlation between age at menopause and brain volume trajectory in older women, highlighting a potentially important factor in women’s neurological health.
Risks Post-Aneurysmal Hemorrhage
Young survivors of aneurysmal subarachnoid hemorrhage continue to face substantial lifelong risks of developing new aneurysms, with a study revealing no plateau in these risks over four decades.
New Alzheimer’s Imaging Agent Approved
The FDA has approved the use of florquinitau F 18 injection (Tauklarify), a PET imaging agent designed to improve Alzheimer’s disease diagnosis and management.
Clinical Hold on Gene Therapy
A clinical trial for the investigational gene therapy clemidsogene lanparvovec (RGX-121), intended for mucopolysaccharidosis type II (Hunter syndrome), has been placed on hold following the identification of small, asymptomatic masses on the spines of five patients.
Neuroprotective Agents and Machine Learning
A study utilized drug screening and machine learning techniques to predict neuroprotective agents in a preclinical model of MPS type IIIA, also known as Sanfilippo syndrome, highlighting innovative approaches in childhood dementia research.
Benzodiazepines in Emergency Situations
Experts have emphasized the necessity of including benzodiazepines in airline emergency medical kits for effectively managing inflight seizures, reinforcing the drug’s critical role in acute care situations.
Valproate Usage and Autism
Research conducted in Taiwan has shown that fathers who used the antiseizure medication valproate prior to conception do not have a higher likelihood of having children with autism or attention deficit-hyperactivity disorder.
Developmental Pathways to Autism
A longitudinal study has proposed new developmental pathways to autism in children diagnosed with tuberous sclerosis complex, expanding our understanding of this complex condition.
New Treatment Options for Alzheimer’s
Eisai has announced that a once-weekly subcutaneous injection of lecanemab (Leqembi Iqlik) is now available as initiation therapy for adults diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Disclaimer
It is important to note that this information is provided for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Fuente: https://www.medpagetoday.com/neurology/generalneurology/122750
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
